Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 5/2009

01-05-2009 | Original Article

Spectroscopic markers of bone quality in alendronate-treated postmenopausal women

Authors: A. L. Boskey, L. Spevak, R. S. Weinstein

Published in: Osteoporosis International | Issue 5/2009

Login to get access

Abstract

Summary

Comparison of infrared spectroscopic images of sections from biopsies of placebo-treated post-menopausal women and women treated for 3 years with 10 mg/day alendronate demonstrated significant increases in cortical bone mineral content, no alterations in other spectroscopic markers of “bone quality,” but a decrease in tissue heterogeneity.

Methods

The material properties of thick sections from iliac crest biopsies of seven alendronate-treated women were compared to those from ten comparably aged post-menopausal women without bone disease, using infrared spectroscopic imaging at ∼7 μm spatial resolution. Parameters evaluated were mineral/matrix ratio, crystallinity, carbonate/amide I ratio, and collagen maturity. The line widths at half maximum of the pixel histograms for each parameter were used as measures of heterogeneity.

Results

The mineral content (mineral/matrix ratio) in the cortical bone of the treated women’s biopsies was higher than that in the untreated control women. Crystallinity, carbonate/protein, and collagen maturity indices were not significantly altered; however, the pixel distribution was significantly narrowed for all cortical and trabecular parameters with the exception of collagen maturity in the alendronate treatment group.

Conclusions

The increases in mineral density and decreased fracture risk associated with bisphosphonate treatment may be counterbalanced by a decrease in tissue heterogeneity, which could impair tissue mechanical properties. These consistent data suggest that alendronate treatment, while increasing the bone mass, decreases the tissue heterogeneity.
Literature
1.
Boskey AL, Mendelsohn R (2005) Infrared spectroscopic characterization of mineralized tissues. Vib Spectrosc 38:107–114PubMedCrossRef
2.
Paschalis EP, DiCarlo E, Betts F et al (1996) FTIR microspectroscopic analysis of human osteonal bone. Calcif Tissue Int 59:480–487PubMed
3.
Paschalis EP, Betts F, DiCarlo E et al (1997) FTIR microspectroscopic analysis of normal human cortical and trabecular bone. Calcif Tissue Int 61:480–486PubMedCrossRef
4.
Paschalis EP, Betts F, DiCarlo E et al (1997) FTIR microspectroscopic analysis of human iliac crest biopsies from untreated osteoporotic bone. Calcif Tissue Int 61:487–492PubMedCrossRef
5.
Paschalis EP, Verdelis K, Doty SB et al (2001) Spectroscopic characterization of collagen cross-links in bone. J Bone Miner Res 16:1821–1828PubMedCrossRef
6.
Paschalis EP, Boskey AL, Kassem M, Eriksen EF (2003) Effect of hormone replacement therapy on bone quality in early postmenopausal women. J Bone Miner Res 18:955–959PubMedCrossRef
7.
Paschalis EP, Recker R, DiCarlo E et al (2003) Distribution of collagen cross-links in normal human trabecular bone. J Bone Miner Res 18:1942–1946PubMedCrossRef
8.
Paschalis EP, Shane E, Lyritis G et al (2004) Bone fragility and collagen cross-links. J Bone Miner Res 19:2000–2004PubMedCrossRef
9.
Boskey AL, DiCarlo E, Paschalis E et al (2005) Comparison of mineral quality and quantity in iliac crest biopsies from high- and low-turnover osteoporosis: an FT-IR microspectroscopic investigation. Osteoporos Int 16:2031–2038PubMedCrossRef
10.
Durchschlag E, Paschalis EP, Zoehrer R et al (2006) Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate. J Bone Miner Res 21:1581–1590PubMedCrossRef
11.
Miller LM, Little W, Schirmer A et al (2007) Accretion of bone quantity and quality in the developing mouse skeleton. J Bone Miner Res 22:1037–1045PubMedCrossRef
12.
Busa B, Miller LM, Rubin CT et al (2005) Rapid establishment of chemical and mechanical properties during lamellar bone formation. Calcif Tissue Int 77:386–394PubMedCrossRef
13.
Silva MJ, Brodt MD, Wopenka B et al (2006) Decreased collagen organization and content are associated with reduced strength of demineralized and intact bone in the SAMP6 mouse. J Bone Miner Res 21:78–88PubMedCrossRef
14.
Lane NE, Yao W, Balooch M et al (2006) Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res 21:466–476PubMedCrossRef
15.
Tumanov AT, Gunyaev GM, Lyutsau VG, Stepanychev EI (1975) Structure, properties, and tests of carbon-reinforced plastics. Mech Compos Mater 11:167–327
16.
National Materials Advisory Board Committee on high-performance synthetic fibers for composites; Commission on Engineering and Technical Systems; National Research Council (1992) High-performance synthetic fibers for composites publication NMAB-458. National Academy Press, Washington, DC, pp 49–103
17.
Smith EJ, McEvoy A, Little DG et al (2004) Transient retention of endochondral cartilaginous matrix with bisphosphonate treatment in a long-term rabbit model of distraction osteogenesis. J Bone Miner Res 19:1698–1705PubMedCrossRef
18.
Burr DB (2002) Bone material properties and mineral matrix contributions to fracture risk or age in women and men. J Musculoskelet Neuronal Interact 2:201–204PubMed
19.
Zoehrer R, Roschger P, Paschalis EP et al (2006) Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women. J Bone Miner Res 21:1106–1112PubMedCrossRef
20.
Roschger P, Dempster DW, Zhou H et al (2007) New observations on bone quality in mild primary hyperparathyroidism as determined by quantitative backscattered electron imaging. J Bone Miner Res 22:717–723PubMedCrossRef
21.
Ruffoni D, Fratzl P, Roschger P et al (2007) The bone mineralization density distribution as a fingerprint of the mineralization process. Bone 40:1308–1319PubMedCrossRef
22.
Roschger P, Pascalis EP, Fratzl P, Klaushofer K (2008) Bone mineralization density distribution in health and disease. Bone 42:456–466PubMedCrossRef
23.
Roschger P, Fratl P, Klaushofer K, Rodan G (1997) Mineralization of cancellous bone after alendronate and sodium fluoride treatment: a quantitative backscattered electron imaging study on minipig ribs. Bone 20:393–397PubMedCrossRef
24.
Roschger P, Rinnerthaler S, Yates J, Rodan GA et al (2001) Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29:185–191PubMedCrossRef
25.
McClung M, Clemmesen B, Daifotis A et al (1998) Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 128:253–261PubMed
26.
Finkelstein JS, Brockwell SE, Mehta V, Greendale GA et al (2008) Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab 93:861–868PubMedCrossRef
27.
Misof BM, Roschger P, Baldini T et al (2005) Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse. Bone 36:150–158PubMedCrossRef
28.
Fratzl P, Roschger P, Fratzl-Zelman N, Paschalis EP et al (2007) Evidence that treatment with risedronate in women with postmenopausal osteoporosis effects bone mineralization and bone volume. Calciif Tissue Int 81:73–80CrossRef
29.
Keaveny TM, Hayes WC (1993) A 20-year perspective on the mechanical properties of trabecular bone. Transact ASME 115:534–554
30.
Goldstein SA (1987) The mechanical properties of trabecular bone: dependence on anatomic location and function. J Biomech 20:1055–1061PubMedCrossRef
31.
Zoehrer R, Roschger P, Duschschlag E, Fratzl P et al (2006) Bone mineralization density distribution in triple biopsies of the iliac crest in post-menopausal women. J Bone Miner Res 21:1106–1112PubMedCrossRef
32.
Boivin GY, Chavassieux PM, Santora AC et al (2000) Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687–694PubMedCrossRef
33.
Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet 348:1535–1541PubMedCrossRef
34.
Bone HG, Hosking D, Devogelaer JP et al (2004) Ten years’ experience with alendronate for osteoporosis in post menopausal women. N Engl J Med 350:1189–1199PubMedCrossRef
35.
Chavassieux PM, Arlot ME, Reda C et al (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475–1480PubMedCrossRef
36.
Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927–2938PubMedCrossRef
37.
Goh SK, Yang KY, Koh JS et al (2007) Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007 89:349–353CrossRef
38.
Lenart B, Lorich DG, Lane JM (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. NEJM 358:1304PubMedCrossRef
39.
Lee P, van der Wall H, Seibel MJ (2007) Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy. J Endocrinol Invest 30:590–597PubMed
40.
Imai K, Yamamoto S, Anamizu Y, Horiuchi T (2007) Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy. J Bone Miner Metab 25:333–336PubMedCrossRef
Metadata
Title
Spectroscopic markers of bone quality in alendronate-treated postmenopausal women
Authors
A. L. Boskey
L. Spevak
R. S. Weinstein
Publication date
01-05-2009
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 5/2009
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-008-0725-9

Other articles of this Issue 5/2009

Osteoporosis International 5/2009 Go to the issue

Original Article

Vertebroplasty and kyphoplasty are associated with an increased risk of secondary vertebral compression fractures: a population-based cohort study

Erratum

Self-reported diseases and the risk of non-vertebral fractures: the Tromsø study

Erratum

Diabetes mellitus and the risk of non-vertebral fractures: the Tromsø Study

Original Article

Hip fracture in the elderly: does counting time from fracture to surgery or from hospital admission to surgery matter when studying in-hospital mortality?

Original Article

Sex-specific association of serum vitamin D levels with physical function in older adults

Original Article

Olympic fencers: adaptations in cortical and trabecular bone determined by quantitative computed tomography